POZ

POZ is a publication that focuses on the experiences of individuals impacted by HIV/AIDS. On its website, Poz.com, you can find daily updates on HIV/AIDS news, information about treatments, as well as forums, blogs, and personal ads.

National, Consumer

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#191376

United States

#86502

Health/Health Conditions and Concerns

#207

Traffic sources

Monthly visitors

Articles

Novel mRNA Technology Coaxes HIV Out of Hiding

3 days ago | poz.com | Liz Highleyman

Researchers have found a way to deliver messenger RNA (mRNA) to latently infected CD4 T cells in the laboratory and coax inactive HIV out of hiding, an approach that could potentially be used for functional cure therapies, according to study results reported in Nature Communications.
What’s in the Pipeline for HIV?

5 days ago | poz.com | Liz Highleyman

The evolution of HIV treatment is among the most remarkable success stories in medical history. From handfuls of pills taken multiple times a day to injections administered just twice a year, antiretroviral therapy has come a long way. Today’s HIV treatment regimens are highly effective and generally well tolerated. What’s more, most people can take a single once-daily pill—similar to taking a statin to manage high cholesterol. But the quest for new longer-acting options continues.
Concerns: Cardiovascular Risk

5 days ago | poz.com | Liz Highleyman

Associations between BMI, excess abdominal fat and cardiovascular disease risk in people with viral suppression on antiretroviral therapy Body mass index (BMI)—a ratio of weight to height—may be a poor measure of cardiovascular disease (CVD) risk for people with HIV, underscoring the importance of more comprehensive screening.
Cure: T-Cell Engager

5 days ago | poz.com | Liz Highleyman

HIV virus particles (purple) budding and replicating from an H9 T cell (green) NIAID In a Phase I/II STRIVE trial, IMC-M113V, an experimental bispecific T-cell engager, was generally safe and well tolerated. Immunocore’s IMC-M113V, an experimental bispecific T-cell engager, may help enable long-term HIV remission.
Funding Cuts Could Increase HIV Cases

5 days ago | poz.com | Liz Highleyman

New HIV diagnoses rose by about 1,000 cases nationwide in 2023, according to the latest surveillance report from the Centers for Disease Control and Prevention (CDC). But these data precede the Trump administration’s recent federal health cuts, and advocates fear that numbers will rise further in the future. Given recent disruptions at the CDC, the fate of this year’s national HIV surveillance update was uncertain, but the agency released key findings in April.
Gender-Affirming Care Linked to Better HIV Outcomes

5 days ago | poz.com | Liz Highleyman

Transgender and nonbinary people who receive gender-affirming hormone therapy may be less likely to acquire HIV and more likely to achieve viral suppression if they do, according to a recent study. In recent years, researchers have made progress in understanding outcomes among trans people living with or at risk for HIV, but political shifts could put further advances in jeopardy.
Can HIV Treatment Lower Cancer Risk?

5 days ago | poz.com | Liz Highleyman

People with HIV who maintain or regain an adequate CD4 T-cell count on antiretroviral treatment are less likely to develop cancer, according to a recent study. Cancer is a growing concern as the HIV population ages. It is well known that people with advanced immune deficiency have an elevated risk for AIDS-defining malignancies, but even less severe impairment can reduce the immune system’s ability to fight cancer.
Prevention: New PEP Options

5 days ago | poz.com | Liz Highleyman

The new guidelines emphasize the importance of starting PEP within 24 hours of exposure if possible. In May, the CDC issued updated guidance for non-occupational HIV post-exposure prophylaxis (PEP)—the first revision since 2016—which now includes more modern antiretrovirals.
Clinical Trials

5 days ago | poz.com | Liz Highleyman

Everything we know about HIV prevention, treatment and the potential for a cure comes from research involving people at risk for or living with the virus. Joining a clinical trial can be a good way to access new therapies and contribute to science, but it’s important to weigh the pros and cons. Clinical trials are a key part of the multistep process for testing new prevention, treatment or cure approaches.
Expanding Access to Long-Acting Injectables

5 days ago | poz.com | Liz Highleyman

Long-acting treatment with Cabenuva (injectable cabotegravir and rilpivirine) can be a feasible option for people who are unable to maintain an undetectable viral load on oral antiretrovirals due to adherence challenges, especially if they receive enhanced support. All modern antiretroviral regimens are effective, so treatment success often comes down to consistent use. Cabenuva is administered by a health care provider once monthly or every other month.